Last reviewed · How we verify
SKLB1028 Dose Escalation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
SKLB1028 Dose Escalation (SKLB1028 Dose Escalation) — CSPC ZhongQi Pharmaceutical Technology Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SKLB1028 Dose Escalation TARGET | SKLB1028 Dose Escalation | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SKLB1028 Dose Escalation CI watch — RSS
- SKLB1028 Dose Escalation CI watch — Atom
- SKLB1028 Dose Escalation CI watch — JSON
- SKLB1028 Dose Escalation alone — RSS
Cite this brief
Drug Landscape (2026). SKLB1028 Dose Escalation — Competitive Intelligence Brief. https://druglandscape.com/ci/sklb1028-dose-escalation. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing